| Literature DB >> 36234974 |
Zehra Edis1,2, Samir Haj Bloukh2,3.
Abstract
Antimicrobial resistance (AMR) is a major concern for the survival of mankind. COVID-19 accelerated another silent pandemic of AMR through the uncontrolled use of antibiotics and biocides. New generations of antimicrobial agents are needed to combat resistant pathogens. Crown ethers can be used as models for drug action because they are similar to antibiotics. Iodine is a well-known microbicide but is characterized by instability and short-term effectivity. Iodine can be stabilized in the form of polyiodides that have a rich topology but are dependent on their immediate surroundings. In addition, copper has been successfully used since the beginning of history as a biocidal agent. We, therefore, combined iodine and copper with the highly selective crown ether 1,4,7,10-tetraoxacyclododecane (12-crown-4). The morphology and composition of the new pentaiodide [Cu(12-crown-4)2]I5 was investigated. Its antimicrobial activities against a selection of 10 pathogens were studied. It was found that C. albicans WDCM 00054 is highly susceptible to [Cu(12-crown-4)2]I5. Additionally, the compound has good to intermediate antimicrobial activity against Gram-positive and Gram-negative bacilli. The chain-like pentaiodide structure is V-shaped and consists of iodine molecules with very short covalent bonds connected to triiodides by halogen bonding. The single crystal structure is arranged across the lattice fringes in the form of ribbons or honeycombs. The susceptibility of microorganisms towards polyiodides depends on polyiodide bonding patterns with halogen-, covalent-, and non-covalent bonding.Entities:
Keywords: antimicrobial; antimicrobial agent; copper; crown ether; halogen bonding; pentaiodide; polyiodide
Mesh:
Substances:
Year: 2022 PMID: 36234974 PMCID: PMC9571227 DOI: 10.3390/molecules27196437
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.927
Figure 1The UV-vis analysis of [Cu(12-crown-4)2]I5.
The UV-vis absorption signals in the samples [Cu(12-crown-4)2]I5 (1), [Rb(12-crown-4)2]I5 (2) [49], and previous reports (nm).
| Group | 1 | 2 | [ | [ | [ | [ | [ |
|---|---|---|---|---|---|---|---|
| I2/12-crown-4 | 204 vs | 204 | 204 | 204 | |||
| I3−/12-crown-4 | 228 s,br | 290 | 228 | 229 | 290 | 223 | 217 |
| I− | 201 vs | 201 | 201 | ||||
| I5− | 445 vw,br | 455 | 450 | 460 |
vw = very weak, br = broad, s = strong, vs = very strong, m = intermediate, exp = experimental, and calc = calculated.
Figure 2The Raman spectroscopic analysis of [Cu(12-crown-4)2]I5.
The Raman shifts of iodine moieties in [Cu(12-crown-4)2]I5 (1), [Cu(H2O)6(12-crown-4)5]I6 x 2I2 (2) [50] and previous reports (cm−1) [22,23,28,39,42,45,47].
| Group | 1. | 2 | [ | [ | [ | [ | [ | [ | [ |
|---|---|---|---|---|---|---|---|---|---|
| I5− Type | V | Y | V | V | V | L | Linear | Linear | |
| Structure | [(I3−)(I2)] | [(I3−)2(I2)0.5] | [(I−)2(I2)] | [(I3−)(I2)] | [(I3−)(I2)] | [(I3−)(I2)] | [(I5−)]n | [(I5−)]n | |
| I2 | s 170 νs | vs 172 νs |
| 177 νs |
|
|
|
| |
| I3- | m, sh [I-I-I−] 71 ν2bend
| 71 ν2bend | 67 ν2bend | 108 νs | 80 ν2bend | 70 ν2bend | |||
| I5- | m,sh 144 νas | m,sh 142 νas | w 144 νas | 151 νas | 147 νas | ||||
| as [I2….I3−] | vw, sh 334 νas | 334 νas | 334 νas | 318 νas | 337 νas | 331 νas | |||
| 12-crown-4 | vw 2926 | vw 2855 |
ν = vibrational stretching, s = symmetric, as = asymmetric, s = strong, m = intermediate, sh = shoulder, v = very, and w = weak, red colored shifts belong to iodine in [….I3−].
Comparative study with [Cu(12-crown-4)2]I5, [Cu(H2O)6(12-crown-4)5]I6 x 2I2 (2) [50], and previous investigations [45,47,49] (cm−1).
| Compound | Type | [I2] | [I3−] | [I2….I3−] | [I3−] | [I2] (cm−1) | [I3−] (cm−1) | [I5−]/[I2….I3−] |
|---|---|---|---|---|---|---|---|---|
| [ | L | 2.75 | 2.83 | 3.38 | 177.45 |
| 80 ν2bend | |
| [ | V | 2.74 | 2.90 | 3.41 | 176.43 |
| 67 ν2bend |
|
| [Cu(H2O)6(12-crown-4)5]I6 x 2I2
| Y | 2.76 | 2.80 | 3.38 | 176.46 | vs 172 νs | m,sh 142 νas | |
| [(I3−)2(I2)0.5]n | 2.77* | 2.93* | 3.38* | |||||
| [Rb(12-crown-4)2]I5 | V | 2.79 | 2.82 | 3.09 | 177.30 |
| 72 ν2bend | s,br 142 νas |
| [Cu(12-crown-4)2]I5 | V | ≥2.77 | ≥2.92 | ≥3.39 | ~180 | s 170 νs | m,sh [I-I-I−] 71 ν2bend
| m,sh 144 νas vw,sh 334 νas |
* average. + expected bond angles for asymmetric triiodide units. ν = vibrational stretching, s = symmetric, as = asymmetric, s = strong, m = intermediate, sh = shoulder, v = very, w = weak, and br = broad. Red/Blue shift in comparison to other bands in Table 3.
Figure 3Comparative analysis of pentaiodides. (a) [Rb(12-crown-4)2]I5 [49]; (b) [(3-HOC5H9NH2)I5] [47]; (c) [Cu(H2O)6(12-crown-4)5]I6 x 2I2 [50]; (d) [(C10H16N2) [I3]2·I2] [45].
The FTIR analysis [cm–1] of 12-crown-4 (1) [50], [Cu(12-crown-4)2]I5 (2), [Cu(12-crown-4)5(H2O)6]I6 x 2I2 (3) [50], and [Rb(12-crown-4)2]I5 (4) [49].
| ν1 (O–H)*s | ν (C–H)as | ν (CH2)as,s | ν (C–H)s | δ (C–H)as | δ (C–C) | δ (C–H) δ (C–C) | ν (C–O) | ν (CH–CH) | |
|---|---|---|---|---|---|---|---|---|---|
| 1 | w 2950 | w 2900 | w 2850 | w 1450 | w 1365 | w 1290 | w 1250 | m 848 | |
| 2 | w,sh 3393 * | w 2953 | w 2905 | w 2859 | w 1445 | w 1362 | w 1287 | w 1248 | s 841 |
| 3 | 3746 *s | 2951 | 2905 | 2863 | 1443 | vw 1360 | 1287 | 1243 | m 844 |
| 4 | 2954 | 2906 | 2865 | 1444 | 1363 | 1289 | 1245 | 849 |
* Signals related to vibrational modes of hydroxyl groups due to hydrogen bonding/intermolecular bonded alcohol and hydration. ν = vibrational stretching, δ = deformation, s = symmetric, as = asymmetric, vs = very strong, s = strong, m = intermediate, w = weak, vw = very weak, and sh = shoulder.
Figure 4The XRD analysis of [Cu(12-crown-4)2]I5.
The XRD analysis of the samples [Cu(12-crown-4)2]I5 (1), pure I2 [25], and previous reports (2Thetao) [30,33].
| Group | 1 | [ | [ | [ | [ |
|---|---|---|---|---|---|
| I2 | 23.1 w | 24.5 s | 22.8 m | 25 | |
| I5− | 15.3 vs | 8 m |
w = weak, s = strong, m = intermediate and v = very.
Figure 5The scanning electron microscopy (SEM) of [Cu(12-crown-4)2]I5 (a) 1μm; (b) 500 nm.
Figure 6Transmission electron microscopy (TEM) of [Cu(12-crown-4)2]I5: (a) 20 nm; (b) 5 nm with average d-spacing of lattice fringes; (c) direction of the main lattice fringes in comparison to the black-white colored barrel-like structures; (d) Energy dispersive spectroscopy (EDS); layered images: (e) all atoms; and (f) I-atom.
Figure 7The transmission electron microscopy (TEM) of [Cu(12-crown-4)2]I5: A deeper look into the structure.
Figure 8The transmission electron microscopy (TEM) of [Cu(12-crown-4)2]I5: (a) 1274% magnification of Figure 6c; (b) electron diffraction pattern along lattice fringe; and illustration of structures (c) ribbon; (d) honeycomb.
Figure 9The transmission electron microscopy (TEM) of [Cu(12-crown-4)2]I5: Electron diffraction pattern along lattice fringes. Main central spots from down-left to up-right 1-2-3 (orange).
The antimicrobial testing of antibiotics (A), title compound (B), and [Cu(12-crown-4)5(H2O)6]I6 x 2I2 (C) [50] by Agar Well (AW) and disc dilution studies (1,2,3). The ZOI (mm) against microbial strains was determined by diffusion assay.
| Strain | Antibiotic | A | AWB | AWC | 1+B | 2+B | 3+B | 1+C | 2+C | 3+C |
|---|---|---|---|---|---|---|---|---|---|---|
| G | 18 | 20 | 20 | 25 | 0 | 0 | 19 | 0 | 0 | |
| G | 28 | 20 | 23 | 11 | 0 | 0 | 35 | 14 | 0 | |
| C | 25 | 25 | 20 | 13 | 0 | 0 | 21 | 0 | 0 | |
| CTX | 25 | 20 | 19 | 16 | 0 | 0 | 18 | 0 | 0 | |
| S | 21 | 19 | 21 | 18 | 12 | 0 | 33 | 11 | 0 | |
| G | 30 | 0 | 0 | 20 | 0 | 0 | 15 | 0 | 0 | |
| CTX | 23 | 17 | 16 | 12 | 0 | 0 | 12 | 0 | 0 | |
| A | 23 | 15 | 15 | 15 | 9 | 0 | 25 | 8 | 0 | |
| CTX | 30 | NA | NA | 16 | 8 | 0 | 24 | 7 | 0 | |
| NY | 16 | 45 | 51 | 25 | 12 | 0 | 53 | 14 | 0 |
Agar well (AW) diffusion studies (20 mg crystals of title compound in a 6 mm diameter well) and disc diffusion studies (6 mm disc impregnated with 2 mL of 50 µg/mL (1), 2 mL of 25 µg/mL (2), and 2 mL of 12.5 µg/mL (3)). A Amikacin (30 µg/disc), G Gentamicin (30 µg/disc), CTX (Cefotaxime) (30 µg/disc), NY (Nystatin) (100 IU), C Chloramphenicol (10 µg/disc), and Streptomycin (10 µg/disc). Grey shaded area represents Gram-negative bacteria. 0 = Resistant. No statistically significant differences (p > 0.05) between row-based values through Pearson correlation.
Figure 10The Agar Well (AW) analysis of the title compound (with concentrations of 11, 5.5, and 2.75 µg/mL). From left to right: (a) C. albicans WDCM 00054; (b) S. aureus ATCC 25932; and (c) S. pneumoniae ATCC 49619.
Figure 11The disc diffusion (DD) studies with positive controls (antibiotic). From left to right: Title compound against (a) C. albicans WDCM 00054; (b) B. subtilis WDCM 00003; and (c) E. coli WDCM 00013.